HitGen Inc. Stock Analysis 688222.SS

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 546 full-time employees. The company went IPO on 2020-04-16. Through the drug discovery and optimization platform, the Company provides clients with services such as screening and optimization of designated biological targets, customized DEL design and synthesis, synthesis and modification of certain designated compounds or nucleic acids and related biological evaluation. The firm is also engaged in the transfer of rights and interests in new drug research projects, capital operations and marketing activities. The firm primarily operates its businesses in the domestic market and overseas markets, including the United States, France, the United Kingdom and Japan.